Related Experiment Video
Updated: Feb 14, 2026

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis
Published on: March 14, 2025
Crizotinib-associated toxic epidermal necrolysis in an ALK-positive advanced NSCLC patient
Shaoyu Yang1, Liming Wu2, Xin Li1
1Department of Medical Oncology, Hangzhou First People's Hospital, Nanjing Medical University, Hangzhou, Zhejiang 310006, P.R. China.
Abstract:
Crizotinib is an oral small-molecule inhibitor of anaplastic lymphoma kinase (ALK) tyrosine-kinase that has been approved for treating patients with advanced echinoderm microtubule associated protein like 4-ALK rearranged non-small-cell lung cancer (NSCLC). Toxic epidermal necrolysis (TEN) is a rare adverse event associated with crizotinib. The present study reported a case of a 75-year-old Chinese male patient with advanced NSCLC with ALK fusion, who developed TEN after 56 days of crizotinib treatment and demised due to this dermatological adverse event. The occurrence of severe cutaneous necrolysis that predominantly involves the skin and mucous membranes during crizotinib treatment should alert clinicians to be aware of TEN and take prompt actions.
Insights
Crizotinib, used for advanced non-small-cell lung cancer (NSCLC), can cause toxic epidermal necrolysis (TEN). This rare but severe skin reaction led to a patient
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Crizotinib is a targeted therapy for anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC).
- Toxic epidermal necrolysis (TEN) is a rare but severe adverse drug reaction.
- Crizotinib has been associated with TEN as a potential side effect.
Purpose of the Study:
- To report a fatal case of TEN in a patient treated with crizotinib for advanced NSCLC.
- To increase awareness among clinicians regarding the risk of TEN during crizotinib therapy.
Main Methods:
- Case report of a 75-year-old Chinese male patient.
- Detailed clinical observation of adverse event development.
- Review of crizotinib treatment and patient outcome.
Main Results:
- The patient developed TEN after 56 days of crizotinib treatment.
- The severe cutaneous adverse event predominantly involved skin and mucous membranes.
- The patient ultimately demised due to the TEN.
Conclusions:
- Clinicians should be vigilant for signs of TEN in patients receiving crizotinib.
- Prompt recognition and management of TEN are crucial to improve patient outcomes.
- This case highlights the potentially fatal nature of crizotinib-induced TEN.
More Related Videos
Related Concept Videos
Positive Regulator Molecules
Position-effect Variegation
Serial Position Effect
Overview of Advanced Functional Groups
Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.
Toxicity Testing in Animals
Renewal of Skin Epidermal Stem Cells

